No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
301257 SMO Clinplus
- 25.62
- -0.79-2.99%
Market Closed Jan 3 15:00 CST
2.04BMarket Cap19.21P/E (TTM)
26.71High25.59Low12.93KlotVolume26.50Open26.41Pre Close33.70MTurnover2.72%Turnover Ratio15.12P/E (Static)79.51MShares49.5352wk High1.79P/B1.22BFloat Cap22.9252wk Low31.69Limit Up47.51MShs Float65.44Historical High21.13Limit Down4.24%Amplitude22.92Historical Low0.33Dividend TTM26.07Avg Price7.10KlotAsk1.29%Div YieldTTM100Lot Size5.34KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Puruis (301257.SZ): Currently not participating in any clinical research projects related to Brain-computer Interface.
On December 19, Gelonghui reported that Pruess (301257.SZ) stated on the investor interaction platform that the company is currently not involved in any clinical research projects related to Brain-computer Interface, and the company will continue to pay attention to Industry trends and customer needs.
Express News | Summary of shareholding reductions of listed companies on December 2.
Express News | Puruis: Shareholders plan to reduce their shareholding by no more than 1.9% of the company's shares.
Express News | 20 companies were surveyed by funds, zhejiang viewshine intelligent meter being the most attention-grabbing among them.
Pures (301257) 2024 third quarter report review: short-term performance under pressure, continuous expansion of personnel.
Event: The company released the third quarter report of 2024, achieving revenue of 0.594 billion yuan in the first three quarters of 2024 (+9.17% year-on-year), achieving a net income attributable to the parent company of 0.072 billion yuan (-28.39% year-on-year).
